Analytical Data
-
Gene name
TEFM
- Application
-
Alternative Names
TEFM; C17orf42; Transcription elongation factor; mitochondrial
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96QE5
-
Expression Region
36-360 aa
-
AA Sequence
KSTTP KKITPNVTFC DENAKEPENA LDKLFSSEQQ ASILHVLNTA STKELEAFRL LRGRRSINIV EHRENFGPFQ NLESLMNVPL FKYKSTVQVC NSILCPKTGR EKRKSPENRF LRKLLKPDIE RERLKAVNSI ISIVFGTRRI AWAHLDRKLT VLDWQQSDRW SLMRGIYSSS VYLEEISSII SKMPKADFYV LEKTGLSIQN SSLFPILLHF HIMEAMLYAL LNKTFAQDGQ HQVLSMNRNA VGKHFELMIG DSRTSGKELV KQFLFDSILK ADPRVFFPSD KIVHYRQMFL STELQRVEEL YDSLLQAIAF YELAVFDSQP
-
Molecular Weight
41.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TEFM (Transcription Elongation Factor, Mitochondrial) is a crucial protein involved in the transcriptional regulation of mitochondrial genes. Its role in maintaining mitochondrial function and integrity has garnered significant interest in recent years, particularly in the context of human diseases such as neurodegenerative disorders, metabolic syndromes, and cancer. Mitochondria are essential organelles responsible for energy production through oxidative phosphorylation, and their dysfunction is linked to numerous pathologies. Research has shown that TEFM assists in stabilizing the transcription machinery and promoting the elongation phase of RNA synthesis in mitochondria, which is vital for the expression of mitochondrial DNA (mtDNA)-encoded genes. Additionally, TEFM interacts with other mitochondrial transcription factors, indicating its participation in a larger regulatory network. Studies on TEFM are exploring its potential as a therapeutic target, with the aim of developing strategies to enhance mitochondrial function or restore normal transcriptional processes in diseased states. As the understanding of TEFM's precise mechanisms and interactions deepens, it may pave the way for innovative interventions to combat various mitochondrial-related diseases. This growing body of research highlights the importance of TEFM not only in basic mitochondrial biology but also in its potential clinical implications, emphasizing the need for continued investigation into its structure, function, and involvement in human health and disease.
